Business
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT) King of
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)\nKing of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Colorado.\nThe presentation, entitled \"PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas\", will highlight results of Phio's Phase 1b clinical study (NCT 06014086) which evaluated the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma.\n\"The clinical study results are encouraging and firmly guide Phio to continued clinical development of this immuno-oncology therapy for cutaneous squamous cell carcinoma,\" said Mary Spellman M.D., Phio's acting Chief Medical Officer. \"Preliminary clinical evidence demonstrates that intratumoral PH-762 may provide substantial clinical benefit, with notable pathologic response, and modest mean reductions in tumor burden following treatment.\"\n\n\n\nPresentation Details for S034 Late-Breaking Research Session 2\n\n\nTitle:\nPD-1 Directed Intratumoral Immunotherapy Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas\n\n\nPresenter:\nMary Spellman, MD, FAAD\n\n\nTime:\n3:00 - 3:12 PM (MDT)\n\n\nDate:\nMarch 28, 2026\n\n\nLocation:\nBellco Theatre, Colorado Convention Center, Denver, Colorado\n\n\n\n \nRecent Company Highlights\nPhio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 8...